Abundant proteins in platelet-rich fibrin and their potential contribution to wound healing: An explorative proteomics study and review of the literature

Emre Yaprak a*, Murat Kasap b, Gurler Akpınar b, Eylul Ece Islek b, Alper Sinanoglu c

a Kocaeli University, Faculty of Dentistry, Department of Periodontology, Kocaeli, Turkey
b Kocaeli University, Faculty of Medicine, Department of Medical Biology, Kocaeli, Turkey
c Kocaeli University, Faculty of Dentistry, Department of Oral and Maxillofacial Radiology, Oral Diagnosis Clinic, Kocaeli, Turkey

Received 27 March 2018; Final revision received 1 July 2018
Available online 3 September 2018

Keywords
Platelet-rich fibrin; Proteomics; MALDI; Blood proteins

Abstract
Background/purpose: It is well-known that diverse types of blood proteins contribute to healing process via different mechanisms. Presence and potential involvements of blood-derived abundant proteins in the platelet-rich fibrin (PRF) to its regenerative capacity have not been sufficiently emphasized in the literature. The aim of this paper was to analyze the abundant proteome content of PRF and summarize previously reported effects of identified proteins on wound healing via a literature review.

Materials and methods: The PRF samples obtained from non-smoking, systemically healthy volunteers were subjected to 2D gel electrophoresis after extracting the proteins from fibrin matrices. All matching spots were excised from the gels and identified by MALDI TOF/TOF MS/MS analysis. A literature review was conducted to reveal possible contributions of identified proteins to wound healing.

Results: Totally, thirty-five blood proteins were commonly identified among all studied samples. These proteins included serine protease inhibitors, such as alpha-1-antitrypsin, alpha-1-antichymotrypsin, alpha-1-acid glycoprotein, inter-alpha-trypsin-inhibitor, protease C1 inhibitor, and complement proteins. In addition, abundant presence of immunoglobulin G was observed. The abundance of albumin, haptoglobin, ceruloplasmin vitronectin, fetuin-A, ficolin-3 and transthrytin was also detected.

Conclusion: The results of this study indicated that PRF abundantly contains blood-origin actors which were previously reported for their direct contribution to wound healing. Further
Introduction

The quality of postoperative wound healing is crucial for the clinical success of surgical treatments. Some important biological processes, such as cell migration/differentiation, angiogenesis and extracellular matrix synthesis are regulated by various growth factors and cytokines which predominantly originate from platelets and leukocytes in the fibrin clot during the wound healing process.1 Adjunctive application of platelet-rich concentrates to the surgical wound sites is done with an expectation that artificially increasing platelets in the wounds may consequently increase the concentration of growth factors, thus accelerate wound healing and improve regenerative potential.2 Platelet-rich concentrates became popular as surgical adjuvants in clinics due to their beneficial effects on the healing process. Accordingly, different types of platelet concentrates and their variations have been developed depending on their preparation protocols.3 In addition, some fibrin-based products including pure fibrin gel or fibrin matrices have been used as supplementary surgical materials.4,5

Among the autologous platelet concentrates, platelet-rich fibrin (PRF) is widely used because it is easy to prepare and is devoid of any foreign agents in its structure.6 Numerous clinical studies have investigated its possible advantages in various oral surgical treatment modalities. Accordingly, application of PRF into 3-wall infrabony defects and mandibular degree II furcation lesions was found to be beneficial with respect to bone filling and clinical attachment gain comparing with open flap debridement alone.7,8 Besides, combination of PRF with some bone graft materials has been found to increase their regenerative potential.9,10 As a sole material or in combination with other biomaterials, using PRF for sinus lifting reportedly improves clinical outcomes.11,12 Beneficial results of PRF application were also reported in other treatment modalities such as socket preservation, alveolar ridge augmentation, and peri-implant guided bone regeneration.13,14

According to the current knowledge, PRF comprises platelets, leukocytes, some circulating stem cells, growth factors, cytokines, and matrix metalloproteinases (MMPs); these are considered to contribute the regenerative potential.15 However, the most accentuated molecules contributing to its regenerative potential are platelet-derived growth factor, transforming growth factor (TGF), vascular endothelial growth factor (VEGF), and insulin-like growth factor.16 Its fibrin network also acts as a biological scaffold and a reservoir for growth factors as it post-operatively enables sustained release of these molecules to an extent.17,18 Some in vitro studies have investigated the biological effects of PRF.19 Accordingly, Dohan Ehrenfest et al.18 reported that PRF stimulates the proliferation and osteoblastic differentiation of human bone mesenchymal cells.20 PRF reportedly promotes bone regeneration by enhancing attachment and proliferation of osteoblasts and production of collagen-related proteins.21 In addition, PRF increases the fibroblast activity in periodontal ligaments by triggering the expression of the in vitro-phosphorylated extracellular signal-regulated protein kinases osteoprotegerin and alkaline phosphatase.22 Moreover, beneficial effects of PRF on the proliferation of human dermal fibroblasts, endothelial cells, keratinocytes, and gingival fibroblasts have also been reported.23–26

Besides being a source of various cell types and growth factors, blood also contains a great variety of proteins that contribute to a broad array of biological processes, including wound healing.27,28 Enhanced wound healing after their separate applications has been demonstrated by experimental studies.29,30 Since PRF is derived from blood, it is highly possible that some of these proteins in the blood may also exist in PRF and its releasate to some extent and may contribute to regenerative potential. However, to our knowledge, proteome profile of PRF has not been documented in the literature. The aim of this exploratory study was to investigate the total protein content of PRF releasate via 2DE-based proteomics analysis and to identify the most abundant proteins in PRF. The potential contribution of the identified proteins to the wound healing process was discussed considering the existing literature on the subject.

Materials and methods

The study was approved by the Ethics Committee of Kocaeli University (GOKAEK 2016/45). Venous blood samples were obtained from eight systemically healthy, non-smoker volunteers (six female and two male; mean age: 29.4 ± 5.6 years) who had not taken any medication during the last month. Approximately 10-mL of venous blood sample was collected without anticoagulants in vacuum plain glass tubes and was immediately centrifuged at approximately 400 g for 10 min.31–35

Preparation of protein samples for 2D

After centrifugation, the PRF fibrin clot in the middle of the tube was separated from the red blood cell base using sterile scissors and tweezers, and the red blood cell layer was also removed to evade proteomic dominance of hemoglobin. The collected PRF fibrin clot was transferred into a new tube without separating the liquid part. To remove the fibrin proteins and to extract PRF releasate, additional

© 2018 Association for Dental Sciences of the Republic of China. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
centrifugation at 20,000 g for 30 min at 4 °C was performed. The resulting supernatant, PRF releasate, rather than the fibrin pellet was then transferred into a new tube and used for further analysis. All materials were stored at −80 °C between all experimental steps.

2D gel electrophoresis

One milligram protein from each protein pool was loaded onto immobilized 17-cm, pH gradient strips (IPG) (pH 3–10NL) by passive rehydration. Separations based on isoelectric points were achieved using a Protean isoelectric focusing cell (Bio-Rad, USA). The strips were run through a stepwise incremental voltage program [250V for 30 min (linear), 4000V for 2.5 h (linear), and 40000 V for 1 h (rapid)]. The plate temperature was maintained at 20 °C. The strips were then subjected to a two-step equilibration in equilibration buffers containing 6M urea, 2% SDS, 0.375M Tris–HCl (pH 8.8), 20% glycerol, and 2% DTT for the first step and the same buffer without DTT but with iodoacetamide (2.5%) for the second step with 20 min of gentle shaking. Following equilibration steps, IPG strips were rinsed with SDS-PAGE running buffer and loaded directly onto 1-mm-thick 12% in-house-made SDS-polyacrylamide gels. The second dimension was accomplished using Dodeca gel running system (BioRad, USA) to minimize gel-to-gel variation. Electrophoresis was carried out at 16 °C at a current intensity of 45 mA/gel until the front dye reached the bottom of the gel. After separation, the gels were fixed in 40% methanol and 10% acetic acid and were then stained with colloidal Coomassie blue G250 (Bio-Rad, USA).

Image analysis

Gel images were captured using VersaDoc MP 4000 (Bio Rad, USA). PDQuest Advance 2D-analysis software (BioRad, USA) was used for comparative analysis of protein spots. The quantity of each spot was normalized by a linear regression model. All matching spots among the gels were selected and excised using ExQuest spot cutter (Bio-Rad, USA) for protein identification.

Protein identification

Protein identification experiments were performed at Kocaeli University DEKARTproteomics laboratory using ABSCIEX MALDI-TOF/TOF 5800 system. In-gel tryptic digestion of proteins was performed using an in-gel digestion kit following the recommended protocol (Pierce, USA). The data obtained from MALDI-TOF/TOF were searched against the MASCOT database version 2.5 (Matrix Science) using a streamline software, ProteinPilot (ABSCIEX, USA), with the following criteria: National Center for Biotechnology Information non-redundant (NCBI nr), species restriction to R. norvegicus, enzyme of trypsin, at least five independent matching peptides, at most one missed cleavage site, MS tolerance set to ±0.05 ppm and MS/MS tolerance set to ±0.4 Da, fixed modification being cells International carboxamidomethyl (Cys) and variable modification being oxidation (Met), a peptide charge of 1+, and being monoisotopic. Only significant hits, as defined by the MASCOT probability analysis (p < 0.05), were accepted.

Results

The samples used in 2D gel electrophoresis were prepared by centrifugation of the PRF-containing fibrin clot. The supernatants collected from this centrifugation were subjected to separation in a pH range of 3–10 using 17-cm IPG strips. A total of 115 ± 10 protein spots was detected in an in silico spot matching experiment (Fig. 1). The overall mean coefficient of variation was 175, indicating that the gels were highly similar in their 2D protein profile. When spot scattering plots were analyzed, an average correlation coefficient value of 0.75 ± 0.15 was obtained. The low correlation coefficient value was due to changes in the quantities of abundant proteins in PRF samples.

A total of 55 spots that were abundantly present in all PRF releasate samples were cut from the gels and identified. Some of the spots were identified twice or more although they were cut from different locations on the gel. This was probably because these proteins are abundant and are thus represented more than one spots or they may be post-translationally modified. After reducing the number of identified proteins by discarding the redundant entries, 35 proteins were identified (Table 1). Some of these proteins were subunits of a protein complex. A detailed literature search revealed that 16 of the identified proteins have been previously reported to be either directly or indirectly linked with the wound healing process (Table 2).

Discussion

Even though it is well-known that the leukocytes, platelets, some growth factors, cytokines and stem cells in PRF are the main actors, exact mechanism of PRF on the wound healing has not been completely revealed.15 According to the hypothesis of this study, since the blood comprises numerous abundant proteins which can affect the wound healing via different mechanisms, some blood-derived proteins existing in PRF may contribute to the regenerative potential. Therefore, it would be worthy to explore the proteins in PRF to identify their potential involvement in wound healing. To our knowledge, no study has investigated the proteomic profile of PRF thus far. Herein, we aimed to investigate the prominent proteins of PRF releasate and discuss their possible contributions to regenerative potential of PRF. The results indicated an abundance of various types of proteins, including complement proteins, serine protease inhibitors, immunoglobulins, and some acute phase proteins, which have been reported to influence the wound healing process by various mechanisms (Table 2). Some of these identified proteins in the PRF releasate are already being used as clinical therapeutic agents and some of them are still being tested experimentally for their potential therapeutic effects.36

Wound healing is an elaborate process comprising the entire period from hemostasis to tissue maturation. This process can be divided into inflammatory, proliferative, and maturational phases. During the inflammation stage, complement proteins have important functions.37 The
blood clot limits the hemorrhage and also acts as an extracellular matrix that enables initial cell migration. Platelet-related secretions, including the growth factors, attract fibroblasts and inflammatory cells to the fibrin clot. After the subsequent activation of the complement cascade, some complement proteins, including complement C3, function as chemoattractants during the recruitment of these cells. Based on beneficial features on wound healing, Sinno et al. topically applied complement C3 protein to experimental cutaneous wounds in rats. They found that complement C3 protein application accelerated the healing with enhanced physical endurance of the wounds when compared to the control group. In addition, increased collagen I and fibronectin levels and inflammatory cell and fibroblast infiltration were detected in C3-treated wounds. Beneficial effects of applying complement C5 protein to wounds have also been reported. The present study revealed the abundance of complement proteins, including complement C3, in PRF. Accordingly, it may be speculated that complement proteins in PRF contribute to the PRF-mediated postoperative wound healing process.

Cell migration/differentiation, angiogenesis, extracellular matrix synthesis, and tissue maturation are regulated by some cytokines and growth factors that interact with various cell types during wound healing. Serine proteases are secreted by neutrophils to control the activity of these molecules. However, prolonged secretion of serine proteases may considerably impair tissue repair. Proteases in wounds may reportedly degrade growth factors and their receptors and consequently prevent complete healing and tissue maturation. However, serine protease inhibitors suppress these devastating effects of serine proteases in the wound region and positively affect wound healing. Various types of serine protease inhibitors that directly contribute to tissue repair have been reported. This study identified the abundance of these protease inhibitors in PRF releasate; the inhibitors included alpha-1-antitrypsin, alpha-1-antichymotrypsin, alpha-1-acid glycoprotein, inter-alpha-trypsin-inhibitor, and protease C1 inhibitor.

Alpha1-antitrypsin and alpha-1-antichymotrypsin are serum-derived protease inhibitors and affect wound healing by inhibiting the activation of pro-MMP-9, a prominent serine protease. Alpha1-antitrypsin is reportedly an anti-inflammatory and anti-apoptotic protein which inhibits pro-cytokine production (IL-1α, IL-6, IL-8, and TNF-α) and increases anti-inflammatory cytokine (IL-10) production. The therapeutic use of alpha-1-antitrypsin and alpha-1-antichymotrypsin on experimental wound models has been demonstrated. For instance, Hoffman et al. used recombinant alpha-1-antichymotrypsin as a therapeutic agent on experimental dermal open wounds in rabbits and found that wound closure was dose-dependently faster in rabbits treated with recombinant alpha-1-antichymotrypsin than in the control group rabbits. Interestingly, Zilm and Bartold reported the presence of alpha-1-antichymotrypsin in porcine enamel matrix derivative (EMD®) and speculated that it contributed to the regenerative potential of EMD. In this study, alpha-1-acid glycoprotein was another protease inhibitor abundantly found in PRF. It is reportedly a potential therapeutic protein for experimental ischemic stroke and acute liver failure and may accelerate wound healing by stimulating fibroblast proliferation and collagen synthesis. Inter-alpha-trypsin-inhibitor is another protease inhibitor found abundantly in PRF in this study. Its potential additive effects on wound healing have
been previously demonstrated.\textsuperscript{51,52} As an acute phase protein circulating in the blood, proteinase C1 inhibitor exhibits protective effects against complement-mediated inflammatory tissue breakdown.\textsuperscript{53} Replacement treatment of C1 inhibitor has been widely used for treating angioedema.\textsuperscript{54} Local administration of C1 inhibitor reduced edema formation and inflammatory tissue damage and increased re-epithelialization in experimental cutaneous burn lesions in animals.\textsuperscript{53,55} Conclusive evidence has proven that systemic administration of C1 inhibitor prevents the formation of secondary ischemic and dermal lesions in the experimental cutaneous burn wounds.\textsuperscript{55,56}

Infection control during periodontal wound healing is crucial due to residual bacteria which make the process more complicated. In addition, postoperatively, improper oral hygiene and subsequent plaque accumulation on the adjacent teeth may influence treatment success.\textsuperscript{57} As demonstrated herein, PRF releasate contains abundant amounts of immunoglobulin G (IgG). Thus, IgGs may provide some infection control against periodontal bacteria during the postoperative wound healing period and may thus consequently contribute to the favorable effects of PRF. Accordingly, it is important to know whether IgGs in PRF actually exhibit a specific antimicrobial activity to the periodontal bacteria during the healing process. Although this possibility has to be investigated by further studies, many studies have reported that blood contains IgG serotypes specific to periodontal pathogens. Papapanou et al.\textsuperscript{58} reported that compared with the controls, chronic periodontitis patients presented with up to 800-fold higher IgG titers as a response to 19 periodontal species.\textsuperscript{58} In fact, the mere presence of periodontal pathogens can increase serum IgG levels to act against periodontal bacteria, indicating that the occurrence of periodontitis is not an obligatory requirement for immune response.\textsuperscript{59} We speculate that the abundant amount of IgG detected in the PRF samples herein may contain IgGs against periodontitis-specific bacteria and thus provide some antibacterial defense and contribute to uneventful healing from PRF application to regenerate damaged periodontal tissues. Therefore, the effect of IgGs in PRF on wound healing.

| #  | Protein Accession | Best Protein Mass | Best Protein Score | Best Protein Description |
|----|------------------|-------------------|--------------------|--------------------------|
| 1  | A1AG2_HUMAN      | 23588             | 400                | Alpha-1-acid glycoprotein 2 |
| 2  | A1AT_HUMAN       | 46707             | 668                | Alpha-1-antitrypsin       |
| 3  | AACT_HUMAN       | 68342             | 672                | Alpha-1-antichymotrypsin  |
| 4  | A1BG_HUMAN       | 54239             | 805                | Alpha-1B-glycoprotein     |
| 5  | ACTB_HUMAN       | 41710             | 656                | Actin, cytoplasmic 1      |
| 6  | AFAM_HUMAN       | 69024             | 609                | Afamin                    |
| 7  | ALBU_HUMAN       | 69321             | 313                | Serum albumin             |
| 8  | AMBP_HUMAN       | 38974             | 360                | Protein AMBP              |
| 9  | APOA1_HUMAN      | 30759             | 592                | Apolipoprotein A-I        |
| 10 | APOE_HUMAN       | 36132             | 685                | Apolipoprotein E          |
| 11 | APOH_HUMAN       | 38273             | 202                | Beta-2-glycoprotein 1 (Apolipoprotein H) |
| 12 | C1S_HUMAN        | 76635             | 344                | Complement C1s subcomponent |
| 13 | CD5L_HUMAN       | 38063             | 601                | CD5 antigen-like          |
| 14 | CERU_HUMAN       | 12128             | 633                | Ceruloplasmin             |
| 15 | CFH1_HUMAN       | 65677             | 215                | Complement factor I        |
| 16 | CLUS_HUMAN       | 52461             | 236                | Clusterin                 |
| 17 | CO4A_HUMAN       | 192650            | 265                | Complement C4-A            |
| 18 | CO3_HUMAN        | 187030            | 393                | Complement C3             |
| 19 | FCN3_HUMAN       | 32882             | 322                | Ficolin-3                 |
| 20 | FETUA_HUMAN      | 39300             | 441                | Alpha-2-HS-glycoprotein (Fetuin-A) |
| 21 | HEMO_HUMAN       | 51643             | 571                | Hemopexin                 |
| 22 | HPT_HUMAN        | 45177             | 324                | Haptoglobin               |
| 23 | IC1_HUMAN        | 55119             | 560                | Plasma protease C1 inhibitor |
| 24 | IGHG1_HUMAN      | 36083             | 353                | Ig gamma-1 chain C region |
| 25 | IGHG2_HUMAN      | 35878             | 115                | Ig gamma-2 chain C region |
| 26 | IGHM_HUMAN       | 49276             | 226                | Ig mu chain C region      |
| 27 | IGKC_HUMAN       | 11602             | 321                | Ig kappa chain C region   |
| 28 | ITIH4_HUMAN      | 103293            | 192                | Inter-alpha-trypsin inhibitor heavy chain H4 |
| 29 | KV302_HUMAN      | 11768             | 223                | Ig kappa chain V–III region SIE |
| 30 | THR8_HUMAN       | 69992             | 533                | Prothrombin               |
| 31 | TPM4_HUMAN       | 28504             | 475                | Tropomyosin alpha-4 chain |
| 32 | TRFE_HUMAN       | 77000             | 1030               | Serotransferrin           |
| 33 | TTHY_HUMAN       | 15877             | 348                | Transthyretin             |
| 34 | VTDB_HUMAN       | 52929             | 848                | Vitamin D-binding protein |
| 35 | VTNC_HUMAN       | 54271             | 482                | Vitronectin               |
cannot be underestimated and should be scrutinized in further studies.

Numerous studies have emphasized on the contributions of some other blood proteins to the wound healing process; these were also identified in our study. Among them, albumin, the most abundant blood protein, was investigated for its potential effects on wound healing. Some reported contributions are as follows: 1) faster wound healing after its topical application in experimental corneal erosions in rabbits. Albumin application provided an anabolic effect during the in vitro bone healing. Anti-oxidant activity via free radical-trapping properties. 2) Accelerating the wound healing via stimulating fibroblast proliferation and collagen synthesis. Alpha1-antitrypsin reducing the activity of MMP-9, anti-inflammatory and anti-apoptotic effects during the healing. 3) Similar effects with Alpha1-antitrypsin during the healing. Accelerated wound closure after the application to experimental dermal open wounds in rabbits. Alpha-2-HS-glycoprotein (Fetuin A) enhancement of wound closure in primary keratinocyte culture.

Table 2: The summarize of reported evidences for possible contributions of some of the identified proteins to the healing process.

| Identified protein                  | Evidence for the possible contribution to healing process                                                                 | Reference |
|------------------------------------|--------------------------------------------------------------------------------------------------------------------------|-----------|
| Albumin                           | Significantly fast healing after topical albumin application in experimental corneal erosions in rabbits. Albumin application provided an anabolic effect during the in vitro bone healing. Anti-oxidant activity via free radical-trapping properties. | 40–62     |
| Alpha1-acid glycoprotein           | Accelerating the wound healing via stimulating fibroblast proliferation and collagen synthesis                               | 43,50     |
| Alpha1-antitrypsin                 | Reducing the activity of MMP-9, anti-inflammatory and anti-apoptotic effects during the healing.                           | 44,45     |
| Alpha1-antichymotrypsin            | Similar effects with Alpha1-antitrypsin during the healing. Accelerated wound closure after the application to experimental dermal open wounds in rabbits. | 30        |
| Alpha-2-HS-glycoprotein (Fetuin A) | Enhancement of wound closure in primary keratinocyte culture.                                                            | 79        |
| Apolipoprotein A-I                 | Promotion of endothelial cell migration. Topical application accelerated the healing of corneal epithelium in experimental dry eye defects. | 71,72     |
| Apolipoprotein E                   | Topical application corrects delayed wound healing in apolipoprotein E deficient mice.                                  | 73        |
| Ceruloplasmin                      | Antioxidant activity in the tissues during the healing. Chaperone activity targeting misfolded proteins during the wound healing. | 75        |
| Complement C3                      | Increased collagen/fibronectin levels and enhanced wound healing were seen in C3 applied experimental cutaneous wounds in rats. | 39        |
| Ficolin-3                          | Participating in the clearance of apoptotic and necrotic cells during the healing.                                        | 77        |
| Haptoglobin                        | Assisting in mitigating the oxidative damage related with neutrophils. Reduces tissue destruction during the inflammation via inhibiting both COX and LOX pathways. Promotes fibroblast migration and inhibits MMP-9 activity during the healing. Stimulation of angiogenesis. Acting as a chaperone targeting misfolded proteins during the wound healing. | 64–67     |
| Inter-alpha-trypsin-inhibitor      | Anti-inflammatory properties during the healing. In vitro extracellular matrix stabilization thought binding to the hyaluronic acid. | 51,52     |
| Protease C1 inhibitor              | Local administration of C1 inhibitor provided inhibition of edema formation, reduction of inflammatory tissue damage and increased reepithelialization in experimental cutaneous burn lesions in animals. | 53,55     |
| Transthyretin                       | Regulation of angiogenesis during the healing.                                                                           | 76        |
| Vitronectin                        | Direct interaction with numerous growth factors and cytokines during the wound healing and thus contributing the wound healing by various aspects. Topical application of vitronectin on experimental corneal defects and tissue cultures resulted in accelerated corneal epithelial wound healing. | 68–70     |

Haptoglobin, another abundant blood protein, acts as a chaperone that targets misfolded proteins during wound healing.63 Furthermore, it assists in mitigating oxidative damage, reduces tissue destruction, promotes fibroblast migration, inhibits MMP activity, and stimulates angiogenesis.64–67 Vitronectin, which is also an abundant blood protein, interacts directly with numerous growth factors and cytokines. Accelerated corneal epithelial wound healing following topical application of vitronectin has also been reported.68–70 A specific group of abundant blood proteins, apolipoproteins, have also been investigated for their potential effects in correcting delayed wound healing; topical application of apolipoprotein E was found to be beneficial in this regard.71–73 Alpha-2-HS-glycoprotein (fetuin-A), another blood protein identified in PRF, possesses some features that contribute to tissue remodeling.74 Like alpha-1-antichymotrypsin, it has also
been found in the proteome of EMD.\textsuperscript{46} Ceruloplasmia, transthyretin, and ficolin-3 were also identified, and their possible associations with wound healing have already been reported.\textsuperscript{75–79}

The possible interactions between some of the identified proteins in PRF releasate and growth factor activity have been documented. Accordingly, albumin reportedly possesses some amino acid sequences which are significantly similar to TGF-β. Concordantly, it has been suggested that albumin activates TGF-β receptor type II and consequent biological pathways owing to its molecular homology with TGF-β.\textsuperscript{80} Vitronectin potentiates VEGF-mediated angiogenesis.\textsuperscript{81} Overexpression of clusterin promotes angiogenesis via VEGF.\textsuperscript{82} Fetuin-A reportedly induces VEGF expression and enhances vascular cell growth in vitro.\textsuperscript{83} Alpha1-antitrypsin increases VEGF expression in different cell types.\textsuperscript{84,85} Alpha1-acid glycoprotein alone induces in vitro endothelial tube formation.\textsuperscript{86} In addition, the proangiogenic properties of alpha-1-acid glycoprotein are attributed to its supportive effect on VEGF.\textsuperscript{87} Complement C3a reportedly increases VEGF expression.\textsuperscript{88}

Studying proteins at the tissue level is challenging.\textsuperscript{88} Tissues in the body comprise various abundant proteins related to their extracellular matrix contents; this makes studying proteomics at a tissue level more complicated than studying proteins in cultured cells. After protein extraction, all proteins in the investigated tissue sample remain in the same test tube. Therefore, due to the domination of abundant proteins in the investigated tissue samples, it is difficult to identify proteins which exist in very small amounts. In this study, since the high abundance of fibrin in PRF is indisputable, we aimed to eliminate it during the protein extraction stage. For this purpose, PRF samples were additionally centrifuged to extract the liquid portion, PRF releasate, completely and let noting but fibrin pellet remains at the bottom of the tubes. Therefore, we did not encounter any spots representing fibrin in 2DE gels. One of the concerns regarding PRF extraction practiced in this study may involve the removal of some “key players” along with the fibrin. However, the centrifugation step used in this study tightly sequesters the fibrin clot and clearly separates the soluble proteome, because it has been done at 20,000 g at 30 min. This centrifugation speed and duration have been used in many publications to prepare cell-free extracts and thus were used in this study as well.\textsuperscript{89,90} On the other hand, there will always be a concern for the fibrin attracted proteins (sponge effect) that may be stacked in between fibrin fibers. We think that those proteins should also be present and representative in the soluble phase. A similar phenomenon is also encountered when abundant proteins are reduced from serum samples using proteominor/MARS depletion kits. But the researches almost always omit those proteins in their analysis.\textsuperscript{81}

The importance of preserving the red blood cell layer on the PRF surface in obtaining more platelets/leukocytes has been emphasized by Dohan Ehrenfest et al.\textsuperscript{92} However, since hemoglobin is another abundant protein along with fibrin, both of which probably preclude the detection of relatively less abundant proteins and thus reduce proteome coverage,\textsuperscript{93} we did not include the red blood cell layer of PRF for analysis. If we had included it during the analysis, we would have potentially been unable to detect some spots representing minor proteins due to the domination of multiple spots representing hemoglobin considering that it is a highly abundant protein. In future studies, identifying the proteome of the hemoglobin-containing layer after hemoglobin depletion may be beneficial to enrich the current proteome map of PRF. Considering that blood is a very rich protein source that represents over 10,000 different proteins,\textsuperscript{94} it is highly possible that PRF may contain a large number of proteins within different quantities in mass. Thus, it would be extremely difficult to reveal the complete proteome map of PRF as it would require step-by-step reduction of abundant proteins and numerous repetitive experiments. Further studies exploring the protein content of PRF are needed to reveal its yet undisclosed potential involvements in the wound healing process.

PRF may be applied directly to the surgical wounds or used as a membrane with most of its liquid part removed. Most of the studies have focused on its fibrin part and growth factors which originate from platelet cells. The results of this study indicated that PRF releasate abundantly contains blood proteins which potentially possess some beneficial effects on wound healing, as discussed above. Therefore, the importance of PRF releasate should not be underestimated.

Considering all the above-discussed data as well as the limitations of our study, it can be speculated that the regenerative potential of PRF may be due to its rich protein content. PRF application may lead to a load of some serine protease inhibitors, complement factors, and immunoglobulins, being unintentionally applied to surgical wounds; these contribute to the overall favorable effects of PRF as discussed. Further studies should confirm if PRF fibrin clot acts as a scaffold and reservoir for these blood proteins and the growth factors.

As this is an explorative research, there is no control group in this study related with its nature. There are numerous similar studies in the literature investigating the proteome profile of targeted biological materials.\textsuperscript{90,95} Accordingly, if we compare the proteome profile of PRF with other biomaterials as control, the identification of various proteins may not be possible due to their possible presence in the control material. The aim of this study was to reveal the prominently expressed proteins in the PRF releasate which potentially contribute to its regenerative potential.

As conclusion, the importance of underestimated and overlooked blood-derived protein factors of the PRF was underlined using the proteomic approach. The beneficial effects of most of the identified proteins have been reported in the literature by in vitro and in vivo studies. The abundance of protease inhibitors, complement proteins, some acute phase proteins, and immunoglobulins in the PRF releasate probably contributes to its regenerative potential in the wound healing process. Further studies exploring the protein content of PRF are needed to reveal its yet undiscovered potential roles in wound healing. The presence and enrichment of these blood proteins should also be considered while developing new modifications of PRF or other types of blood-derived biomaterials in future.
Conflicts of interest
The authors declare no conflicts of interest related to this study.

Acknowledgments
This study was financially supported by Kocaeli University Scientific Research Projects Fund, Turkey (Grant ID:2016/031).

References

1. Polimeni G, Xiropaidis AV, Wikesjo UM. Biology and principles of periodontal wound healing/regeneration. Periodontol 2000 2006;1:30–47.
2. Prakash S, Thakur A. Platelet concentrates: past, present and future. J Maxillofac Oral Surg 2011;10:45–9.
3. Ehrenfest DMD, Rasmusson L, Albrektsson T. Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). Trends Biotechnol 2009;27:158–67.
4. Lai VK, Frey CR, Kerandi AM, et al. Microstructural and mechanical differences between digested collagen-fibrin co-gels and pure collagen and fibrin gels. Acta Biomater 2012;8:4031–42.
5. Noori A, Ashrafi SJ, Vaez-Ghaemi R, et al. A review of fibrin and fibrin composites for bone tissue engineering. Int J Nanomed 2017;12:4937–61.
6. Castro AB, Meschi N, Temmerman A, et al. Regenerative potential of Leucocyte- and Platelet Rich Fibrin (L-PRF). Part A: intrabony defects, furcation defects, and periodontal plastic surgery. A systematic review and meta-analysis. J Clin Peri odontol 2017;44:67–82.
7. Pradeep AR, Rao NS, Agarwal E, et al. Comparative evaluation of autologous platelet-rich fibrin and platelet-rich plasma in the treatment of 3-wall intrabony defects in chronic periodontitis: a randomized controlled clinical trial. J Periodontol 2012;83:1499–507.
8. Bajaj P, Pradeep AR, Agarwal E, et al. Comparative evaluation of autologous platelet-rich fibrin and platelet-rich plasma in the treatment of mandibular degree II furcation defects: a randomized controlled clinical trial. J Periodontal Res 2013;48:573–81.
9. Pradeep AR, Karvekar S, Nagpal K, et al. Rosuvastatin 1.2 mg in situ gel combined with 1:1 mixture of autologous platelet-rich fibrin and porous hydroxyapatite bone graft in surgical treatment of mandibular class II furcation defects: a randomized clinical control trial. J Periodontol 2016;87:5–13.
10. Kim BJ, Kwon TK, BaeK HS, et al. A comparative study of the effectiveness of sinus bone grafting with recombinant human bone morphogenetic protein 2-coated tricalcium phosphate and platelet-rich fibrin-mixed tricalcium phosphate in rabbits. Oral Surg Oral Med Oral Pathol Oral Radiol 2012;113:583–92.
11. Ali S, Bakry SA, Abd-Elhakam H. Platelet-rich fibrin in maxillary sinus augmentation: a systematic review. J Oral Implantol 2015;41:746–53.
12. Simonpieri A, Choukroun J, Del Corso M, et al. Simultaneous sinus-lift and implantation using microthreaded implants and leukocyte- and platelet-rich fibrin as sole grafting material: a six-year experience. Implant Dent 2011;20:2–12.
13. Hauser F, Gaydarov N, Badour I, et al. Clinical and histological evaluation of postextraction platelet-rich fibrin socket filling: a prospective randomized controlled study. Implant Dent 2013;22:295–303.
14. Naik B, Karunakar P, Jayadev M, et al. Role of platelet rich fibrin in wound healing: a critical review. J Conserv Dent 2013;16:284–93.
15. Eren G, Gurkan A, Atmaca H, et al. Effect of centrifugation time on growth factor and MMP release of an experimental platelet-rich fibrin-type product. Platelets 2016;27:427–32.
16. Dohan DM, Choukroun J, Diss A, et al. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part II: platelet-related biologic features. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;101:e45–50.
17. Kang YH, Jeon SH, Park JY, et al. Platelet-rich fibrin is a bio-scaffold and reservoir of growth factors for tissue regeneration. Tissue Eng Pt A 2011;17:349–59.
18. Dohan Ehrenfest DM, de Peppo GM, Doglioli P, et al. Slow release of growth factors and thrombospondin-1 in Chouk- roun’s platelet-rich fibrin (PRF): a gold standard to achieve for all surgical platelet concentrates technologies. Growth Factors 2009;27:63–9.
19. Miron RJ, Fujioka-Kobayashi M, Bishara M, et al. Platelet-rich fibrin and soft tissue wound healing: a systematic review. Tissue Eng Part B Rev 2016.
20. Dohan Ehrenfest DM, Doglioli P, de Peppo GM, et al. Chou- kroun’s platelet-rich fibrin (PRF) stimulates in vitro proliferation and differentiation of human oral bone mesenchymal stem cell in a dose-dependent way. Arch Oral Biol 2010;55:185–94.
21. Wu CL, Lee SS, Tsai CH, et al. Platelet-rich fibrin increases cell attachment, proliferation and collagen-related protein expression of human osteoblasts. Aust Dent J 2012;57:207–12.
22. Chang YC, Zhao JH. Effects of platelet-rich fibrin on human periodontal ligament fibroblasts and application for periodontal infrabony defects. Aust Dent J 2011;56:365–71.
23. Lundquist R, Dziegiel MH, Agren MS. Bioactivity and stability of endogenous fibrogenic factors in platelet-rich fibrin. Wound Repair Regen 2008;16:356–63.
24. Roy S, Driggs J, Elgharably H, et al. Platelet-rich fibrin matrix improves wound angiogenesis via inducing endothelial cell proliferation. Wound Repair Regen 2011;19:753–66.
25. Clinet F, Tricot S, Alno N, et al. In vitro effects of Choukroun’s platelet-rich fibrin conditioned medium on 3 different cell lines implicated in dental implantology. Implant Dent 2012;21:51–6.
26. Vahabi S, Vaziri S, Torshabi M, et al. Effects of plasma rich in growth factors and platelet-rich fibrin on proliferation and viability of human gingival fibroblasts. J Dent (Tehran) 2015;12:504–12.
27. Burnouf T, Gobrann HA, Chen TM, et al. Blood-derived bio- materials and platelet growth factors in regenerative medi- cine. Blood Rev 2013;27:77–89.
28. Powanda MC, Moyer ED. Plasma proteins and wound healing. Surg Gynecol Obstet 1981;153:749–55.
29. Han YP, Yan C, Garner WL. Proteolytic activation of matrix metalloproteinase-9 in skin wound healing is inhibited by alpha-1-antichymotrypsin. J Invest Dermatol 2008;128:2334–42.
30. Hoffmann DC, Textoris C, Oehme F, et al. Pivotal role for alpha-1-antichymotrypsin in skin repair. J Biol Chem 2011;286:28889–901.
31. Dohan DM, Choukroun J, Diss A, et al. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part I: technological concepts and evolution. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;101:e37–44.
32. Kanoriya D, Pradeep AR, Garg V, et al. Mandibular degree II furcation defects treatment with platelet-rich fibrin and 1% alendronate gel combination: a randomized controlled clinical trial. J Periodontol 2016;87:2281–8.
33. Kanoriya D, Pradeep AR, Singh S, et al. Synergistic approach using platelet-rich fibrin and 1% alendronate for intrabony defect treatment in chronic periodontitis: a randomized clinical trial. J Periodontol 2016;87:1427–35.
34. Sharma A, Pradeep AR. Autologous platelet-rich fibrin in the treatment of mandibular degree II furcation defects: a randomized clinical trial. J Periodontol 2011;82:1396–403.
35. Pradeep AR, Garg V, Kanoriya D, et al. Platelet-rich fibrin with 1.2% rosuvastatin for treatment of intrabony defects in chronic periodontitis: a randomized controlled clinical trial. J Periodontol 2016;87:1468–73.
36. Cazander G, Jukema GN, Nibbering PH. Complement activation and inhibition in wound healing. Clin Dev Immunol 2012;2012:534291.
37. Sinno H, Prakash S. Complements and the wound healing cascade: an updated review. Plast Surg Int 2013;2013:146764.
38. Nakagawa H, Sunada Y, Ando Y. Biological activities of C3 beta c, a novel neutrophil chemoattractant derived from the beta-chain of rat complement C3. Immunology 1998;94:253–7.
39. Sinno H, Malhoitra M, Lutfy J, et al. Topical application of complement C3 in collagen formulation increases early wound healing. J Dermatol Treat 2013;24:141–7.
40. Sinno H, Malhoitra M, Lutfy J, et al. Accelerated wound healing with topical application of complement C5. Plast Reconstr Surg 2012;130:523–9.
41. Wilgus TA, Roy S, McDaniel JC. Neutrophils and wound repair: positive actions and negative reactions. Adv Wound Care (New Rochelle) 2013;2:379–88.
42. McCarty SM, Percival SL. Proteases and delayed wound healing. Adv Wound Care (New Rochelle) 2013;2:438–47.
43. Maeda H, Murakami O, Kann M, et al. The growth-stimulating effect of alpha 1-acid glycoprotein in cells in culture. J Cell Physiol 1980;163:223–7.
44. Grimstein C, Choi YK, Satoh M, et al. Combination of alpha-1 antitrypsin and doxycycline suppresses collagen-induced arthritis. J Gene Med 2010;12:35–44.
45. Janciauskiene SM, Nita IM, Stevens T. Alpha1-antitrypsin, old and new tricks. Alpha1-antitrypsin exerts in vitro anti-inflammatory activity in human monocytes by elevating cAMP. J Biol Chem 2007;282:8573–82.
46. Zilm PS, Bartold PM. Proteomic identification of proteinase inhibitors in the porcine enamel matrix derivative, EMD(R). J Periodontal Res 2011;46:111–7.
47. Moldthana HL, Hirko AC, Thinschmidt JS, et al. Alpha 1-antitrypsin therapy mitigated ischemic stroke damage in rats. J Stroke Cerebrovas Dis 2014;23:e355–63.
48. Toldo S, Seropian IM, Mezzaroma E, et al. Alpha-1 antitrypsin inhibits caspase-1 and protects from acute myocardial ischemia-reperfusion injury. J Mol Cell Cardiol 2011;51:244–51.
49. Jedicke N, Struever N, Aggrawal N, et al. alpha-1-antitrypsin inhibits acute liver failure in mice. Hepatology 2014;59:2299–308.
50. Hochepieled T, Berger FG, Baumann H, et al. Alpha(1)-acid glycoprotein: an acute phase protein with inflammatory and immunomodulating properties. Cytokine Growth Factor Rev 2003;14:25–34.
51. Garantiotsi S, Zudaire E, Trempos CS, et al. Serum inter-alpha-trypsin inhibitor and matrix hyaluronan promote angiogenesis in fibrotic lung injury. Am J Respir Crit Care Med 2008;178:939–47.
52. Zhuo L, Kimata K. Structure and function of inter-alpha-trypsin inhibitor heavy chains. Connect Tissue Res 2008;49:311–20.
53. Kirschfink M, Nurnberger W. C1 inhibitor in anti-inflammatory therapy: from animal experiment to clinical application. Mol Immunol 1999;36:225–32.
54. Bork K, Staubach P, Hardt J. Treatment of skin swellings with C1-inhibitor concentrate in patients with hereditary angioedema. Allergy 2008;63:751–7.
55. Begieneman MP, Kubat B, Ulrich MM, et al. Prolonged C1 inhibitor administration improves local healing of burn wounds and reduces myocardial inflammation in a rat burn wound model. J Burn Care Res 2012;33:544–51.
56. Henze U, Lennartz A, Hafemann B, et al. The influence of the C1-inhibitor BERINERT and the protein-free haemodialysate ACTIHAEMYL20% on the evolution of the depth of scald burns in a porcine model. Burns 1997;23:473–7.
57. Korman KS, Robertson PB. Fundamental principles affecting the outcomes of therapy for osseous lesions. Periodontol 2000 2000;22:22–43.
58. Papapanou PN, Neiderud AM, Disick E, et al. Longitudinal stability of serum immunoglobulin G responses to periodontal bacteria. J Clin Periodontol 2004;31:985–90.
59. Pussinen PJ, Kononen E, Paju S, et al. Periodontal pathogen carriage, rather than periodontitis, determines the serum antibody levels. J Clin Periodontal 2011;38:405–11.
60. Higuchi A, Ueno R, Shimamura S, et al. Albumin rescues ocular epithelial cells from cell death in dry eye. Curr Eye Res 2007;32:83–8.
61. Yamaguchi M, Igarashi A, Misawa H, et al. Enhancement of albumin expression in bone tissues with healing rat fractures. J Cell Biochem 2003;89:356–63.
62. Danielsen PL, Agren MS, Jorgensen LN. Platelet-rich fibrin versus albumin in surgical wound repair: a randomized trial with paired design. Ann Surg 2010;251:825–31.
63. Yerbury JJ, Rybchyn MS, Easterbrook-Smith SB, et al. The acute phase protein haptoglobin is a mammalian extracellular chaperone with an action similar to clusterin. Biochemistry 2005;44:10914–25.
64. Quaye IK. Haptoglobin, inflammation and disease. Trans R Soc Trop Med Hyg 2008;102:735–42.
65. Saeed SA, Ahmad N, Ahmed S. Dual inhibition of cyclooxygenase and lipooxygenase by human haptoglobin: its polymorphism and relation to hemoglobin binding. Biochem Biophys Res Commun 2007;353:915–20.
66. de Kleijn DP, Smeets MB, Kemmeren PP, et al. Acute-phase protein haptoglobin is a cell migration factor involved in arterial restructuring. Faseb J 2002;16:1123–5.
67. Jain S, Gautam V, Naseem S. Acute-phase proteins: as diagnostic tool. J Pharm BioAllied Sci 2011;3:118–27.
68. Kabata T, Ishibashi Y, Honmura S, et al. Effect of vitronectin on the healing of rabbit corneal epithelial damage. Nippon Ganka Gakkai Zasshi 1990;94:457–61.
69. Chow S, Di Girolamo N. Vitronectin: a migration and wound healing factor for human corneal epithelial cells. Invest Ophthalmol Vis Sci 2014;55:6590–600.
70. Leavestey DL, Kashyap AS, Croll T, et al. Vitronectin-master controller or micromanager? IUBMB Life 2013;65:807–18.
71. Nyunt AK, Ishida Y, Yu Y, et al. Topical apolipoprotein A-1 may have a beneficial effect on the corneal epithelium in a mouse model of dry eye: a pilot study. Eye Contact Lens 2008;34:287–92.
72. Kimura T, Sato K, Malchinkhuu E, et al. High-density lipoprotein stimulates endothelial cell migration and survival through sphingosine 1-phosphate and its receptors. Arterioscler Thromb Vasc Biol 2003;23:1283–8.
73. Gordts SC, Muthuramu I, Amin R, et al. The impact of lipoproteins on wound healing: topical HDL therapy corrects delayed wound healing in apolipoprotein E deficient mice. Pharmaceuticals (Basel) 2014;7:419–32.
74. Szweras M, Liu D, Partridge EA, et al. Alpha 2-HS glycoprotein/ fetuin, a transforming growth factor-beta/bone morphogenetic protein antagonist, regulates postnatal bone growth and remodeling. J Biol Chem 2002;277:19991–7.
75. Rathore KI, Kerr BJ, Redensek A, et al. Ceruloplasmin protects against bone loss and reduces myocardial inflammation in a rat burn wound model. J Biol Chem 2013;288:31752–60.
77. Kuraya M, Ming Z, Liu X, et al. Specific binding of L-ficolin and H-ficolin to apoptotic cells leads to complement activation. Immunobiology 2005;209:689–97.

78. Zuliani-Alvarez L, Midwood KS. Fibrinogen-related proteins in tissue repair: how a unique domain with a common structure controls diverse aspects of wound healing. Adv Wound Care (New Rochelle) 2015;4:273–85.

79. Wang XQ, Hayes MT, Kempf M, et al. Fetuin-A: a major fetal serum protein that promotes “wound closure” and scarless healing. J Invest Dermatol 2008;128:753–7.

80. Siddiqui SS, Siddiqui ZK, Malik AB. Albumin endocytosis in endothelial cells induces TGF-beta receptor II signaling. Am J Physiol Lung Cell Mol Physiol 2004;286:L1016–26.

81. Li R, Luo M, Ren M, et al. Vitronectin regulation of vascular endothelial growth factor-mediated angiogenesis. J Vasc Res 2014;51:110–7.

82. Fu Y, Lai Y, Wang Q, et al. Overexpression of clusterin promotes angiogenesis via the vascular endothelial growth factor in primary ovarian cancer. Mol Med Rep 2013;7:1726–32.

83. Siegel-Axel DI, Ultrich S, Stefan N, et al. Fetuin-A influences vascular cell growth and production of proinflammatory and angiogenic proteins by human perivascular fat cells. Diabetologia 2014;57:1057–66.

84. Petrache I, Fijalkowska I, Zhen L, et al. A novel antiapoptotic role for alpha1-antitrypsin in the prevention of pulmonary emphysema. Am J Respir Crit Care Med 2006;173:1222–8.

85. Bellacen K, Kalay N, Ozeri E, et al. Revascularization of pancreatic islet allografts is enhanced by alpha-1-antitrypsin under anti-inflammatory conditions. Cell Transplant 2013;22:2119–33.

86. Irmak S, Oliveira-Ferrer L, Singer BB, et al. Pro-angiogenic properties of orosomucoid (ORM). Exp Cell Res 2009;315:3201–9.

87. Long Q, Cao X, Bian A, et al. C3a increases VEGF and decreases PDE5 mRNA levels in human retinal pigment epithelial cells. BioMed Res Int 2016;2016:6958752.

88. Yang S, Huang CM. Recent advances in protein profiling of tissues and tissue fluids. Expert Rev Proteomics 2007;4:515–29.

89. Ozgul S, Kasap M, Akpinar G, et al. Linking a compound-heterozygous Parkin mutant (Q311R and A371T) to Parkinson’s disease by using proteomic and molecular approaches. Neurochem Int 2015;85:86–11–13.

90. Yaprac E, Kasap M, Akpinar G, et al. The prominent proteins expressed in healthy gingiva: a pilot exploratory tissue proteomics study. Odontology 2018;106:19–28.

91. Krief G, Deutsch O, Gariba S, et al. Improved visualization of low abundance oral fluid proteins after triple depletion of alpha amylase, albumin and IgG. Oral Dis 2011;17:45–52.

92. Dohan Ehrenfest DM, Del Corso M, Diss A, et al. Three-dimensional architecture and cell composition of a Choukroun’s platelet-rich fibrin clot and membrane. J Periodontol 2010;81:546–55.

93. Ringrose JH, van Solinge WW, Mohammed S, et al. Highly efficient depletion strategy for the two most abundant erythrocyte soluble proteins improves proteome coverage dramatically. J Proteome Res 2008;7:3060–3.

94. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002;1:845–67.

95. Reichenberg E, Redlich M, Cancemi P, et al. Proteomic analysis of protein components in periodontal ligament fibroblasts. J Periodontol 2005;76:1645–53.